AbbVie (ABBV) Research & Development (2012 - 2026)
AbbVie (ABBV) reported Research & Development of $2.5 billion for Q1 2026, up 19.59% year-over-year from $2.1 billion in Q1 2025, and down 4.15% on a QoQ basis from $2.6 billion in Q4 2025.
AbbVie (ABBV) has 15 years of Research & Development data on file, last reported at $2.5 billion in Q1 2026.
- Quarterly Research & Development rose 19.59% year-over-year to $2.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.5 billion (down 26.46% YoY) and the FY2025 annual result came in at $9.1 billion, down 28.89% from the prior year.
- Research & Development eased to $2.5 billion in Q1 2026 per ABBV's latest filing, from $2.6 billion in the prior quarter.
- Across five years, Research & Development topped out at $6.8 billion in Q4 2024 and bottomed at $1.5 billion in Q1 2022.
- The 5-year median for Research & Development is $1.9 billion (2024), against an average of $2.3 billion.
- The widest annual swing landed in 2024, when Research & Development jumped 251.53%; it then tumbled 61.93% in 2025.
- Tracing ABBV's Research & Development over 5 years: stood at $1.8 billion in 2022, then rose by 7.65% to $1.9 billion in 2023, then jumped by 251.53% to $6.8 billion in 2024, then plunged by 61.93% to $2.6 billion in 2025, then declined by 4.15% to $2.5 billion in 2026.
- Per Business Quant, the three latest ABBV Research & Development figures stand at $2.5 billion (Q1 2026), $2.6 billion (Q4 2025), and $2.3 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 3.51 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 3.53 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 2.47 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 12.59 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.72 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 1.37 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.49 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.65 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.47 Bn |
| Dec 31, 2025 | 2.58 Bn |
| Sep 30, 2025 | 2.32 Bn |
| Jun 30, 2025 | 2.13 Bn |
| Mar 31, 2025 | 2.07 Bn |
| Dec 31, 2024 | 6.77 Bn |
| Sep 30, 2024 | 2.13 Bn |
| Jun 30, 2024 | 1.95 Bn |
| Mar 31, 2024 | 1.94 Bn |
| Dec 31, 2023 | 1.93 Bn |
| Sep 30, 2023 | 1.72 Bn |
| Jun 30, 2023 | 1.73 Bn |
| Mar 31, 2023 | 2.29 Bn |
| Dec 31, 2022 | 1.79 Bn |
| Sep 30, 2022 | 1.61 Bn |
| Jun 30, 2022 | 1.61 Bn |
| Mar 31, 2022 | 1.50 Bn |
| Dec 31, 2021 | 1.83 Bn |
| Sep 30, 2021 | 1.66 Bn |
| Jun 30, 2021 | 1.77 Bn |
| Mar 31, 2021 | 1.67 Bn |
| Dec 31, 2020 | 1.71 Bn |
| Sep 30, 2020 | 1.71 Bn |
| Jun 30, 2020 | 1.58 Bn |
| Mar 31, 2020 | 1.38 Bn |
| Dec 31, 2019 | 1.54 Bn |
| Sep 30, 2019 | 2.29 Bn |
| Jun 30, 2019 | 1.29 Bn |
| Mar 31, 2019 | 1.29 Bn |
| Dec 31, 2018 | 6.50 Bn |
| Sep 30, 2018 | 1.27 Bn |
| Jun 30, 2018 | 1.32 Bn |
| Mar 31, 2018 | 1.24 Bn |
| Dec 31, 2017 | 1.41 Bn |
| Sep 30, 2017 | 1.23 Bn |
| Jun 30, 2017 | 1.23 Bn |
| Mar 31, 2017 | 1.14 Bn |
| Dec 31, 2016 | 1.21 Bn |
| Sep 30, 2016 | 1.11 Bn |
| Jun 30, 2016 | 35.00 Mn |
| Mar 31, 2016 | 946.00 Mn |
| Dec 31, 2015 | 1.08 Bn |
| Sep 30, 2015 | 350.00 Mn |
| Jun 30, 2015 | 981.00 Mn |
| Mar 31, 2015 | 811.00 Mn |
| Dec 31, 2014 | 500.00 Mn |
| Sep 30, 2014 | 812.00 Mn |
| Jun 30, 2014 | 834.00 Mn |
| Mar 31, 2014 | 772.00 Mn |
| Dec 31, 2013 | 798.00 Mn |
| Sep 30, 2013 | 714.00 Mn |
| Jun 30, 2013 | 709.00 Mn |
| Mar 31, 2013 | 634.00 Mn |
| Dec 31, 2012 | 681.00 Mn |
| Sep 30, 2012 | 813.00 Mn |
| Jun 30, 2012 | 642.00 Mn |
| Mar 31, 2012 | 642.00 Mn |